Repligen Corporation

NASDAQ:RGEN

Medical - Instruments & Supplies

Healthcare
$172.67 -2.74%

-$3.66 today

Market cap
$11.04B
Beta
1.08
P/E (TTM)
142.4
EPS (TTM)
$0.91
52W Low $100.99High $175.77

Volume 1.30M

Average 1.08M

RGEN EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Repligen CorporationNASDAQ: RGEN

EBITDA · Q2 FY2026 · quarter ended Jun 2026

EBITDA dips below year-ago levels

Q2 FY2026 EBITDA of $45.92M fell 5.0% year over year, behind the +55.7% change in trailing-twelve-month EBITDA. Sequentially, it rose 42.1% from the prior quarter. Over 3 fiscal years it compounded at -13.0% a year.

Context

  • EBITDA amounted to 24.7% of revenue in FY2025, up 12.1 pp from a year earlier.
  • EBITDA increased in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 15 analysts of $255.33M (+39.9%) for the fiscal year ending Dec 2026, a slowdown from the +127.4% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$45.92M+42.1% QoQ
Last fiscal yearDec 2025
$182.51M+127.4% YoY
LTMJun 2026
$174.78M+55.7% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-5.0%+21.9%+26.9 pp
1 year+127.4%+39.9%-87.5 pp
3-year CAGR-13.0%+27.7%+40.7 pp
5-year CAGR+23.0%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
182.51M USD
Year-over-year change
+127.4%
4-year CAGR
-2.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How RGEN compares with its peers on the latest reported figures

  • RGEN's LTM Jun 2026 EBITDA of $174.78M is the 6th highest of the 9 companies compared; the peer median is $421.73M.
  • Its year-over-year change of +55.7% is the 2nd highest of 9, against a peer median of -1.2%.
  • EBITDA amounts to 22.3% of revenue for RGEN, versus a peer median of 25.2%.
RGEN Competitors Peer median
EBITDA for RGEN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TMOThermo Fisher Scientific Inc.LTM Sep 2026$11.24B -0.8%-1.3%23.7%
AAgilent Technologies, Inc.LTM Jul 2026$2.04B +13.2%-1.2%27.6%
QGENQiagen N.V.LTM Jun 2026$703.39M -1.6%-2.7%33.5%
BIOBio-Rad Laboratories, Inc.LTM Jun 2026$514.7M -22.7%—19.9%
TECHBio-Techne CorporationLTM Sep 2026$328.77M +48.3%-9.1%26.8%
RGENRepligen CorporationLTM Jun 2026$174.78M +55.7%-13.0%22.3%
AVTRAvantor, Inc.LTM Jun 2026$125.3M -91.1%-55.0%1.9%
BLFSBioLife Solutions, Inc.LTM Mar 2026-$7.46M -184.6%—7.5%
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026-$55.57M +77.9%—26.6%
Peer median (excluding RGEN) $421.73M-1.2%-2.7%25.2%

Competitors are the stored peer set for RGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue670.53M801.54M632.36M634.44M738.26M
Cost of Revenue279.28M345.83M353.92M359.79M390.63M
Gross Profit391.25M455.71M278.44M274.65M347.62M
Gross Margin58.3%56.9%44.0%43.3%47.1%
Research & Development34.27M43.94M42.72M43.2M54.18M
Selling, General & Admin183.87M215.83M218.58M263.37M290.51M
Operating Expenses224.01M231.04M230.74M309.76M288.05M
Depreciation & Amortization38.45M57.01M86.11M86.56M96.96M
EBITDA203.27M277.31M145.32M80.26M182.51M
EBITDA Margin30.3%34.6%23.0%12.7%24.7%
Operating Income167.25M224.67M47.7M(35.11M)59.58M
Operating Margin24.9%28.0%7.5%-5.5%8.1%
Interest Income176K6.98M0027.57M
Interest Expense12.71M2.98M10.03M22.57M23.17M
Other Income / Expenses(13.71M)(5.53M)9M8.08M2.81M
Income Before Tax153.54M219.14M56.71M(27.04M)62.38M
Pre-Tax Margin22.9%27.3%9.0%-4.3%8.5%
Income Tax Expense25.25M33.18M21.11M(1.52M)13.49M
Net Income128.29M185.96M35.6M(25.51M)48.89M
Net Margin19.1%23.2%5.6%-4.0%6.6%
EPS (Basic)2.333.350.64(0.46)0.87
EPS (Diluted)2.243.240.63(0.46)0.86
Weighted Avg Shares55.02M55.46M55.72M55.94M56.23M
Weighted Avg Shares (Diluted)57.26M57.46M56.38M55.94M56.56M

Repligen Corporation

NASDAQ:RGEN

Intrinsic Alpha fair value

Locked

Current Price

$172.67

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.